WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
-
Leerink Partners 6th Annual Global
Healthcare Conference
February 15, 2017 at 1:00pm ET -
2017 RBC Capital Markets Global Healthcare Conference
February 23, 2017 at 9:30am ET -
Cowen and Company 37th Annual Health Care
Conference
March 7, 2017 at 8:40am ET
The webcasts will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available at the same location for approximately a week.
About ImmunoGen
ImmunoGen is a clinical-stage biotechnology
company that develops targeted cancer therapeutics using its proprietary
antibody-drug conjugate technology. ImmunoGen’s lead product candidate,
mirvetuximab soravtansine, is in a Phase 3 trial for folate receptor
alpha (FRα)-positive platinum-resistant ovarian cancer, and is in
Phase 1b/2 testing in combination regimens for earlier-stage disease.
ImmunoGen’s ADC technology is used in Roche’s marketed product, Kadcyla®,
in three other clinical-stage ImmunoGen product candidates, and in
programs in development by partners Amgen, Bayer, Biotest, CytomX,
Lilly, Novartis, Sanofi and Takeda. More information about the Company
can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170202006257/en/
